Positive: Selling, general, and administrative costs amounted to 105.4millionfor2020and104.2 million for 2019, marking an increase of 1.2million.Therisewasprimarilyduetoa5.1 million uptick in service fees to our PPN partners, likely because they dispensed more XHANCE prescriptions; a 1.9millionboostinpersonnel−relatedcosts,includingstockoptions,drivenbyalargerworkforce;a0.8 million climb in insurance and infrastructure costs; an increase of 0.7millioninbaddebtprovisions;anda0.4 million rise in market access costs. This growth was partly counterbalanced by a 5.1millionreductionrelatedtopostponedornon−occurringexpensesstemmingfromtheoperationalimpactsofCOVID−19onareassuchasmarketingandtravel;a1.7 million downturn in direct-to-consumer marketing expenditures; and a 0.9millioncutbackinpatent,legal,consulting,andprofessionalfees.Thenetinterestexpensewas12.6 million in 2020 versus 7.3millionin2019.Theriseinnetinterestexpensein2020originatedfromanelevatedprincipalonthePharmakonSeniorSecuredNotes,mitigatedby0.4 million in interest income. Additionally, interest income dropped by $1.9 million from 2019 due to lower interest rates.
Negative: Selling, general, and administrative costs amounted to 105.4millionfor2019and104.2 million for 2020, indicating a decrease of 1.2million.Thisreductionwasmainlyduetoa5.1 million decline in service fees to our PPN partners, likely because they dispensed fewer XHANCE prescriptions; a 1.9millionreductioninpersonnelcostsincludingstockcompensationsresultingfromadecreasedheadcount;a0.8 million cut in insurance and infrastructure costs; a 0.7milliondecreaseinbaddebtexpenses;alongwitha0.4 million reduction in market access expenses. The downturn was complemented by a 5.1millionincreaseassociatedwithexpeditedorunavoidableexpenses,irrespectiveofCOVID−19′seffectonbusinessoperations,notablymarketingandsellinginitiatives,aswellastravel;a1.7 million increase in direct-to-consumer marketing expenses; and an additional 0.9millioninpatent,legal,consulting,andprofessionalfees.Interestincomeexceedednetinterestexpense,amountingto12.6 million in 2019 compared to 7.3millionin2020.Thedeclineininterestexpense,net,for2020derivedfromadiminishedprincipalbalanceofthePharmakonSeniorSecuredNotesoffsetbyinterestexpensesof0.4 million. Interest income surged by $1.9 million as compared to 2019 due to higher interest rates.